GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hua Medicine (HKSE:02552) » Definitions » 5-Year ROIIC %

Hua Medicine (HKSE:02552) 5-Year ROIIC % : 45.68% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Hua Medicine 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Hua Medicine's 5-Year ROIIC % for the quarter that ended in Dec. 2023 was 45.68%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Hua Medicine's 5-Year ROIIC % or its related term are showing as below:

HKSE:02552's 5-Year ROIIC % is ranked better than
86.63% of 950 companies
in the Drug Manufacturers industry
Industry Median: 3.5 vs HKSE:02552: 45.68

Hua Medicine 5-Year ROIIC % Historical Data

The historical data trend for Hua Medicine's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hua Medicine 5-Year ROIIC % Chart

Hua Medicine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year ROIIC %
Get a 7-Day Free Trial - - -105.86 -16.18 45.68

Hua Medicine Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
5-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -16.18 - 45.68 -

Competitive Comparison of Hua Medicine's 5-Year ROIIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hua Medicine's 5-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Hua Medicine's 5-Year ROIIC % falls into.



Hua Medicine 5-Year ROIIC % Calculation

Hua Medicine's 5-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( -316.203 (Dec. 2023) - -453.522 (Dec. 2018) )/( 320.319 (Dec. 2023) - 19.696 (Dec. 2018) )
=137.319/300.623
=45.68%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Hua Medicine  (HKSE:02552) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Hua Medicine 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Hua Medicine's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Hua Medicine Business Description

Traded in Other Exchanges
Address
Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. The group majorly operates in the PRC.
Executives
Hlyy Limited 2306 Nominee for another person
Tct (bvi) Limited 2501 Other
The Core Trust Company Limited 2301 Trustee
Hong Jane Xingfang 2202 Interest of your spouse
Chen Li 2101 Beneficial owner
Wuxi Pharmatech Investments (cayman) Inc. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Investment Holdings (cayman) Inc. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Fund I General Partner L.p. 2201 Interest of corporation controlled by you
Wuxi Pharmatech Healthcare Fund I L.p. 2101 Beneficial owner
Wuxi Apptec Co., Ltd. 2201 Interest of corporation controlled by you
Wuxi Apptec International Holdings Limited 2201 Interest of corporation controlled by you
Nelsen Robert Taylor 2101 Beneficial owner
Venrock Management V, Llc 2102 Investment manager
Harvest Yuanxiang (cayman) Limited 2101 Beneficial owner
Arch Venture Fund Vii, L.p. 2101 Beneficial owner

Hua Medicine Headlines

No Headlines